Instability of GATA3 or BRCA1 Gene is Associated to Breast Cancer: Case Study in Benin

Callinice D. Capo-chichi^{1, 2,} , Sara Y. Houngue^{1, 2} and Freddy H.R. Gnangnon²

¹Department of Biochemistry and molecular biology, University of Abomey Calavi (UAC), Abomey Calavi, Benin

²Division of Molecular Biomarker in Cancer and Nutrition (BMCN), Cotonou, Benin

Cite this paper:
Callinice D. Capo-chichi, Sara Y. Houngue and Freddy H.R. Gnangnon. Instability of GATA3 or BRCA1 Gene is Associated to Breast Cancer: Case Study in Benin. Journal of Cancer Research and Treatment. 2025; 13(1):1-6. doi: 10.12691/jcrt-13-1-1

Abstract

Breast cancer is the number 1 silent killer of women in Benin. For preventive screening some women relies on lump palpation and often disregard molecular biomarker profiling that could prevent them from developing this disease if performed early. Our objective is to investigate the biomarkers involved in breast cell differentiation (GATA3), growth regulation and genomic stability (BRCA1) to delineate them as biomarker to screen for breast cancer risk ahead of clinical symptoms. Key exons involved in each biomarker function are investigated Materials and methods: Upon ethical approval and signed informed consent, microbiopsy tissues was collected from 54 women diagnosed with breast cancer. Exon 4 of GATA3, Exon 1 and Exon 2 of BRCA1 were amplified by polymerase chain reaction (PCR) to investigate their integrity. The presence of amplification with one band is classified as no abnormality, the absence of amplification is classified as deletion while the presence of multiple bands is classified as polymorphism (mutation). Protein expression of GATA3 and BRCA1 were determined by western blot with anti-GATA3 and anti-BRCA1 IgG. Results: The PCR analyses revealed that in 13% cases, all 3 biomarkers targeted sequence were mutated and not amplified. Regarding GATA3-exon 4 amplification, 31% of samples have only 1 band while 54% have more than 2 bands. Regarding BRCA1-exon 1, one band is present in 63% while for BRCA1-exon 2 one band is present in 48% of samples. The Chi square test showed that GATA3-exon 4 and BRCA1-exon 2 have significant inverse variation (p < 0.05). Western blot analyses showed an existence of heterogeneity in GATA3 protein profile with many mutant bands while BRCA1 protein is absent in the majority of samples. Conclusion: It is worthy to emphasis a molecular screening for breast cancer patients before commencing therapy to prevent drug resistance due to matchless between cancer initiation mechanism and targeted therapy.

Keywords:
Breast cancer GATA3-exon 4 BRCA1-Exon 2 genes proteins

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Bates DL, Chen Y, Kim G, Guo L, Chen L. Crystal structures of multiple GATA zinc fingers bound to DNA reveal new insights into DNA recognition and self-association by GATA. J Mol Biol. 2; 381(5): 1292–1306, Jul 2008.
[2]	Takaku M, Grimm SA, Wade PA. GATA3 in breast cancer: tumor suppressor or oncogene? Gene Expr.; 16(4): 163–168, Dec 2015.
[3]	Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol; 9(2): 201-9, Feb 2007.
[4]	Tindemans I, Serafini N, Di Santo JP, Hendriks RW. GATA-3 function in innate and adaptive immunity. Immunity; 41(2): 191-206, Aug 2014.
[5]	Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res.; 67(13): 6477-83, Jul 2007.
[6]	Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol.; 15(2): 201-13, Feb 2013.
[7]	Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem.; 285(18): 14042–51, Apr 2010.
[8]	Capo-chichi CD, Gnangnon F, Mekpossi C, Houngue S, Xu XX, Olory-Togbé JL. Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells. Journal of Cancer Research and Treatment; 6(3), 60-69, Aug 2018.
[9]	Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M et al. Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. GigaScience; 4:50, Nov 2015.
[10]	Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer.; 7(12): 937-48, Dec 2007.
[11]	Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. J Clin Oncol,; 27(27): 4515-21, Sep 2009.
[12]	Capo-Chichi CD, Aguida B, Gnangnon F, et al. Altered expression of BRCA1/2 proteins in breast cancer in Benin. Conference: 6ème Colloque de l’Université d’Abomey-Calavi (UAC), Benin. 25-30 sept 2017.
[13]	Hounguè S, Totah T, George S, Jean-Léon Olory-Togbé JL, Capo-chichi CD. BRCA1 Protein Deficiency in Breast Cancer Microbiopsy Lysate Delineates Patient Survival Time. Journal of Cancer Research and Treatment.; 9(1), 1-11.
[14]	Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ, Harkin DP, Mullan PB. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene; 31, 3667–3678, Aug 2012.
[15]	Arnold JM, Choong DY, Thompson ER, Waddell N, Lindeman GJ, Visvader JE et al. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat.; 119(2): 491-6, Jan 2010.
[16]	Lara K, Consigliere N, Pérez J, Porco A. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res.; 45(2): 117-30, 2012.
[17]	Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S et al. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol.; 41(12): 1794-801, Dec 2010.
[18]	Xu AP, Xu LB, Smith ER, Fleishman JS, Chen ZS, Xu XX. Cell death in cancer chemotherapy using taxanes. Front Pharmacol.; 14: 1338633, Jan 2024.
[19]	Jivani A, Shinde RK. A Comprehensive Review of Taxane Treatment in Breast Cancer: Clinical Perspectives and Toxicity Profiles. Cureus.; 16(4): e59266, Apr 2024.
[20]	Chen MC, Hsu SL, Lin H, Yang TY. Retinoic acid and cancer treatment. Biomedicine (Taipei).; 4(4): 22, 2014.
[21]	Esposito M, Kang Y. RAI2: linking retinoic acid signaling with metastasis suppression. Cancer Discov.; 5(5): 466-8, May 2015.